000145071 001__ 145071
000145071 005__ 20240926122722.0
000145071 0248_ $$2sideral$$a139870
000145071 037__ $$aART-2021-139870
000145071 041__ $$aeng
000145071 100__ $$0(orcid)0000-0002-6546-6149$$aBellés, Andrea$$uUniversidad de Zaragoza
000145071 245__ $$aEffects of lactoferrin on the microbiota in a murine model of antibiotics-induced dysbiosis. P0201. 29th United European Gastroenterology Week Virtual 2021
000145071 260__ $$c2021
000145071 5060_ $$aAccess copy available to the general public$$fUnrestricted
000145071 5203_ $$aIntroduction: The antibiotic administration can result in gut microbiota alterations that impact health, for instance the selection of opportunistic pathogens. In this context, the search for modulators of microbiota that prevent the side effects of antibiotics is an interesting field of research. Bovine lactoferrin is a milk protein with numerous effects: anticancer, anti-inflammatory, antimicrobial and immune modulator activities [1] . However, its potential to counteract the side effects of antibiotics on the microbiota has not been fully studied. Aims & Methods: The aim was to study the ability of native and saturated lactoferrin to reverse the effects of clindamycin on the intestinal microbiota in a murine model. Male C57BL/6 mice of 8 weeks old were randomly divided into six groups (n=5 per group): vehicle, clindamycin (Clin), native bovine lactoferrin (nLf), nLf + clindamycin (nLf_Clin), iron-saturated bovine lactoferrin (sLf) and sLf + clindamycin (sLf_Clin). Vehicle received saline orally for 10 days. Clin was gavaged for 10 days with saline and on day 4 received a single IP injection of 200 µg of clindamycin. nLf and sLf were gavaged for 10 days with 35 mg of nLf or sLf respectively. The groups nLf_Clin and sLf_Clin were gavaged with nLf or sLf and on day 4 received an injection of clindamycin. To corroborate the effects of the treatments, a second experiment was performed in the same way with male C57BL/6 mice of 12 weeks old (same breeder one year later). Faecal samples were obtained from the mice at the end of the treatments. After extracting DNA from faecal samples (QIAamp Fast DNA Stoool Mini Kit, Qiagen), the V4 region of the bacterial 16S rRNA gene was amplified. Sequencing of the libraries was performed by Miseq platform (Illumina) and 2 x 250 bp paired-end reads were obtained.Sequence data were quality filtered, and differences in the composition and alpha and beta diversity were analysed using QIIME2 and R softwares. Results: The taxonomic composition analysis revealed that most sequences were assigned to Firmicutes and Bacteroidota phyla. The Verrucomicrobiota, Proteobacteria and Actinobacteriota phyla were also present in all groups of treatment, although in lower proportions. We analysed the bacterial communities of the groups in terms of alpha and beta-diversity. The number of different ASVs observed in most samples was in the range of 200-800. The Shannon index was in the range of 3.5-5, indicating the well-known high diversity of the gut bacterial community. No differences were found in the Shannon index of the 8 weeks old groups of treatment (p > 0,05). However, in experiment with 12 weeks old mice, the Shannon indexes in nLf, nLf_Clin and sLf_Clin groups were statistically lower than vehicle (p < 0,05). Bray-Curtis beta diversity indices showed that the microbial community of vehicle was statistically different from the communities of Clin, nLf_Clin and sLf_Clin in both experiments. At family level, Bacteriodaceae, Prevotellaceae and Rikenellaceae decreased in Clin group. The treatment with nLf or sLf along with clindamycin could revert these effects, increasing the levels of bacteria in all these families.
Conclusion: Clindamycin induces alterations in the composition of the murine intestinal microbiota, reducing bacteria with anti-inflammatory properties such as Bacteriodaceae, Prevotellaceae or Rikenellaceae. Lactoferrin restores the normal levels of these anti-inflammatory bacteria and, therefore, could be a candidate for use as prebiotic in functional foods.
000145071 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000145071 590__ $$a6.866$$b2021
000145071 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b23 / 92 = 0.25$$c2021$$dQ1$$eT1
000145071 592__ $$a1.445$$b2021
000145071 593__ $$aOncology$$c2021$$dQ1
000145071 593__ $$aGastroenterology$$c2021$$dQ1
000145071 594__ $$a7.9$$b2021
000145071 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000145071 700__ $$0(orcid)0000-0002-1829-6319$$aAguirre-Ramírez, Diego
000145071 700__ $$aAbad, Inés
000145071 700__ $$0(orcid)0000-0001-5964-823X$$aSánchez, Lourdes$$uUniversidad de Zaragoza
000145071 700__ $$0(orcid)0000-0002-5306-9365$$aGrasa, Laura$$uUniversidad de Zaragoza
000145071 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000145071 7102_ $$12008$$2780$$aUniversidad de Zaragoza$$bDpto. Produc.Animal Cienc.Ali.$$cÁrea Tecnología de Alimentos
000145071 773__ $$g9, 8 (2021), p. 375$$pUnited European Gastroenterol. j.$$tUnited European Gastroenterology Journal$$x2050-6406
000145071 8564_ $$s571315$$uhttps://zaguan.unizar.es/record/145071/files/texto_completo.pdf$$yVersión publicada
000145071 8564_ $$s1717835$$uhttps://zaguan.unizar.es/record/145071/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000145071 909CO $$ooai:zaguan.unizar.es:145071$$particulos$$pdriver
000145071 951__ $$a2024-09-26-10:58:53
000145071 980__ $$aARTICLE